An update on the medical therapy of advanced metastatic renal cell carcinoma

Stephan Kruck; Axel S. Merseburger; Georgios Gakis; Mario W. Kramer; Arnulf Stenzl; Markus A. Kuczyk

doi:10.1080/00365590802203983

An update on the medical therapy of advanced metastatic renal cell carcinoma

Stephan Kruck, Axel S. Merseburger, Georgios Gakis, Mario W. Kramer, Arnulf Stenzl, Markus A. Kuczyk

Department of Urology

7 Citations (Scopus)

Abstract

The effectiveness of multikinase inhibitors in first- and second-line therapy of metastatic renal cell carcinoma (RCC) has been evaluated in various clinical studies. Initial results indicate an increased response rate and a prolonged progression-free survival compared with cytokine-containing therapeutic approaches. The new multitargeted kinase inhibitors sorafenib (Nexavar®/BAY 43-9006) and sunitinib (Sutent®/SUO 11248) interfere mainly with vascular endothelial growth factor and platelet-derived growth factor pathways. Recently, temsirolimus, a specific inhibitor of mammalian target of rapamycin, demonstrated activity in RCC patients with poor prognosis. This review discusses the effectiveness of the most frequently used substances for systemically progressive RCC in consideration of the currently available clinical data.

Original language	English
Journal	Scandinavian Journal of Urology and Nephrology
Volume	42
Issue number	6
Pages (from-to)	501-506
Number of pages	6
ISSN	0036-5599
DOIs	https://doi.org/10.1080/00365590802203983
Publication status	Published - 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Research Area: Luebeck Integrated Oncology Network (LION)

Access to Document

10.1080/00365590802203983

Cite this

@article{e282290db6444d61b587f678c8315d3f,

title = "An update on the medical therapy of advanced metastatic renal cell carcinoma",

abstract = "The effectiveness of multikinase inhibitors in first- and second-line therapy of metastatic renal cell carcinoma (RCC) has been evaluated in various clinical studies. Initial results indicate an increased response rate and a prolonged progression-free survival compared with cytokine-containing therapeutic approaches. The new multitargeted kinase inhibitors sorafenib (Nexavar{\textregistered}/BAY 43-9006) and sunitinib (Sutent{\textregistered}/SUO 11248) interfere mainly with vascular endothelial growth factor and platelet-derived growth factor pathways. Recently, temsirolimus, a specific inhibitor of mammalian target of rapamycin, demonstrated activity in RCC patients with poor prognosis. This review discusses the effectiveness of the most frequently used substances for systemically progressive RCC in consideration of the currently available clinical data.",

author = "Stephan Kruck and Merseburger, \{Axel S.\} and Georgios Gakis and Kramer, \{Mario W.\} and Arnulf Stenzl and Kuczyk, \{Markus A.\}",

year = "2008",

doi = "10.1080/00365590802203983",

language = "English",

volume = "42",

pages = "501--506",

journal = "Scandinavian Journal of Urology and Nephrology",

issn = "0036-5599",

publisher = "Informa Healthcare",

number = "6",

}

TY - JOUR

T1 - An update on the medical therapy of advanced metastatic renal cell carcinoma

AU - Kruck, Stephan

AU - Merseburger, Axel S.

AU - Gakis, Georgios

AU - Kramer, Mario W.

AU - Stenzl, Arnulf

AU - Kuczyk, Markus A.

PY - 2008

Y1 - 2008

N2 - The effectiveness of multikinase inhibitors in first- and second-line therapy of metastatic renal cell carcinoma (RCC) has been evaluated in various clinical studies. Initial results indicate an increased response rate and a prolonged progression-free survival compared with cytokine-containing therapeutic approaches. The new multitargeted kinase inhibitors sorafenib (Nexavar®/BAY 43-9006) and sunitinib (Sutent®/SUO 11248) interfere mainly with vascular endothelial growth factor and platelet-derived growth factor pathways. Recently, temsirolimus, a specific inhibitor of mammalian target of rapamycin, demonstrated activity in RCC patients with poor prognosis. This review discusses the effectiveness of the most frequently used substances for systemically progressive RCC in consideration of the currently available clinical data.

AB - The effectiveness of multikinase inhibitors in first- and second-line therapy of metastatic renal cell carcinoma (RCC) has been evaluated in various clinical studies. Initial results indicate an increased response rate and a prolonged progression-free survival compared with cytokine-containing therapeutic approaches. The new multitargeted kinase inhibitors sorafenib (Nexavar®/BAY 43-9006) and sunitinib (Sutent®/SUO 11248) interfere mainly with vascular endothelial growth factor and platelet-derived growth factor pathways. Recently, temsirolimus, a specific inhibitor of mammalian target of rapamycin, demonstrated activity in RCC patients with poor prognosis. This review discusses the effectiveness of the most frequently used substances for systemically progressive RCC in consideration of the currently available clinical data.

UR - https://www.scopus.com/pages/publications/56749169190

U2 - 10.1080/00365590802203983

DO - 10.1080/00365590802203983

M3 - Scientific review articles

C2 - 18615363

AN - SCOPUS:56749169190

SN - 0036-5599

VL - 42

SP - 501

EP - 506

JO - Scandinavian Journal of Urology and Nephrology

JF - Scandinavian Journal of Urology and Nephrology

IS - 6

ER -

An update on the medical therapy of advanced metastatic renal cell carcinoma

Abstract

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Fingerprint

Cite this